Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
07:01am, Friday, 09'th Jun 2023
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?
12:38pm, Thursday, 08'th Jun 2023
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
Why Shares of Iovance Biotherapeutics Jumped Tuesday
04:18pm, Tuesday, 30'th May 2023
The FDA set a PDUFA date of Nov. 25 for cell-therapy lifileucel. Iovance focuses on T-cell therapies to treat various cancers.
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application
11:27am, Tuesday, 30'th May 2023
Iovance Biotherapeutics Inc. NASDAQ: IOVA shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Administration (FDA). The company submitted, and the FDA
Biotech Stock Surges on FDA Update
11:24am, Tuesday, 30'th May 2023
The shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) were last seen up 10.7% to trade at $8.36, after the U.S. Food and Drug Administration (FDA) reportedly accepted the company's license applic
Iovance Biotherapeutics shares rally on receiving FDA priority review for melanoma drug
09:52am, Tuesday, 30'th May 2023
Iovance Biotherapeutics (NASDAQ:IOVA) told investors that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for lifileucel for patients with advanced melan
FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug
11:20am, Monday, 29'th May 2023
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1
01:41pm, Wednesday, 10'th May 2023
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2023 Earnings Call Transcript
10:26pm, Tuesday, 09'th May 2023
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Co
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
04:01pm, Tuesday, 02'nd May 2023
SAN CARLOS, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
Iovance Biotherapeutics to Present at Upcoming Conferences
07:01am, Monday, 24'th Apr 2023
SAN CARLOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance Progresses Despite Challenges In Developing Potency Assays For Lifileucel
05:10am, Sunday, 23'rd Apr 2023
Iovance Progresses Despite Challenges In Developing Potency Assays For Lifileucel.
Wall Street Thinks These 2 Nasdaq Stocks Could Go Parabolic Soon
09:45am, Thursday, 20'th Apr 2023
Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.
Iovance Biotherapeutics: Looking Towards Successful FDA Review In 2023
12:43am, Wednesday, 19'th Apr 2023
Iovance Biotherapeutics: Looking Towards Successful FDA Review In 2023
Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?
12:56pm, Thursday, 30'th Mar 2023
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?
